Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xospata

- PMLiVE

Keytruda gains NICE clearance in first line bladder cancer

MSD extends advantage in immunotherapy with Cancer Drugs Fund clearance

Sanofi reception

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body

- PMLiVE

EMA starts review of Xtandi in non-metastatic prostate cancer

The evaluation is based on positive results from the PROSPER trial

- PMLiVE

NICE says OK to Keytruda for bladder cancer via the CDF

Becomes the first immunotherapy recommended for UC after chemotherapy

- PMLiVE

Merck and Pfizer set to win NICE backing for Bavencio

The PD-L1 inhibitor is being assessed for the treatment of mMCC patients

- PMLiVE

Pfizer’s leukaemia drug Mylotarg backed for use in EU

The CHMP’s positive opinion could see the drug return to market after almost eight years

EISAI

NICE reverses its rejection of Eisai’s Lenvima

The cost-effectiveness watchdog has now backed the thyroid cancer treatment

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

Roche Basel Switzerland

NICE backs Roche’s Gazyvaro after initial rejection

An undisclosed discount swayed the cost-effectiveness body

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

- PMLiVE

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

Findings demonstrated a 71% reduction in cancer spreading and death

- PMLiVE

Astellas strengthens US and Canadian leadership team

Steve Sabus, Lynn Gerber and Kevin O’Keefe are promoted to new roles

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links